Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.

Davies, Jessica, Martinec, Michael, Delmar, Paul, Coudert, Mathieu, Bordogna, Walter, Golding, Sophie, Martina, Reynaldo ORCID: 0000-0002-1925-820X and Crane, Gracy (2018) Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib. Journal of Comparative Effectiveness Research, 7 (9). pp. 855-865.

Text Manuscript_V2_5June18_Clean.docx - Author Accepted Manuscript Download (432kB)

Abstract

To compare the overall survival of anaplastic lymphoma kinase-positive non-small-cell lung cancer patients who received alectinib with those who received ceritinib.Two treatment arms (alectinib [n = 183] and ceritinib [n = 67]) were extracted from clinical trials and an electronic health record database, respectively. Propensity scores were applied to balance baseline characteristics. Kaplan-Meier and multivariate Cox regression were conducted.After propensity score adjustment, baseline characteristics were balanced. Alectinib had a prolonged median overall survival (alectinib = 24.3 months and ceritinib = 15.6 months) and lower risk of death (hazard ratio: 0.65; 95% CI: 0.48-0.88).Alectinib was associated with prolonged overall survival versus ceritinib, which is consistent with efficacy evidence from clinical trials.

Item Type:	Article
Uncontrolled Keywords:	comparative effectiveness, non-small-cell lung cancer, real-world evidence
Depositing User:	Symplectic Admin
Date Deposited:	02 Oct 2018 13:37
Last Modified:	19 Jan 2023 01:15
DOI:	10.2217/cer-2018-0032
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3026962